Page 92 - 《中国药科大学学报》2025年第5期
P. 92

学报
               624                 Journal of China Pharmaceutical University 2025, 56(5): 624 − 633


                              基于网络药理学探究藏药佐汤卡擦丸治疗

                                             高血压的药理作用机制


                                                                  1
                                                                                          1,3*
                                                                             2
                            1#
                    更 桑 ,邹欣欣 ,白玛罗布 ,扎西道知 ,纪雪娇 ,多杰仁青 ,黄凤杰                                              2**
                                                     1
                                       2#
                       ( 西藏藏医药大学附属医院, 拉萨         850000; 中国药科大学多靶标天然药物全国重点实验室, 南京               211198;
                                                       2
                       1
                                                西藏藏医药大学基础部, 拉萨         850000)
                                               3
               摘 要 通过网络药理学和体内实验探究藏药佐汤卡擦丸(ZTKCW)治疗高血压的作用机制。利用网络药理学筛选                                      68 个
               ZTKCW  活性成分和    518 个药物-疾病靶点,通过网络拓扑分析筛选出鸭嘴花考林酮碱、木犀草素、异紫堇球碱、秦皮乙素、甘
               草素等   8 个  ZTKCW  标志性核心成分和     AKT1、TNF、IL6、STAT3 等  8 个关键靶点。KEGG    富集分析表明核心靶点主要富集
               在脂质与动脉粥样硬化、JAK-STAT         和炎症相关信号通路。采用自发性高血压大鼠(SHR)进行体内实验,分别用                            0.41、
               0.82 和  1.64 g/kg 的  ZTKCW  灌胃  12 周。结果显示,1.64 g/kg ZTKCW  显著降低  SHR  大鼠的收缩压和舒张压,并降低胸主动
               脉和心脏中     AKT1、PI3K、STAT3 和  JAK2 的磷酸化水平。本研究证明        ZTKCW  可能通过   PI3K/AKT  和  JAK2/STAT3 通路发
               挥降压作用,为     ZTKCW  用于高血压治疗提供了思路和理论基础。
               关键词 高血压;佐汤卡擦丸;网络药理学;作用机制
               中图分类号  R285;R965       文献标志码 A        文章编号 1000−5048(2025)05−0624−10
                                                     doi:10.11665/j.issn.1000−5048.2025040102

                引用本文 更桑,邹欣欣,白玛罗布,等. 基于网络药理学探究藏药佐汤卡擦丸治疗高血压的药理作用机制                        [J]. 中国药科大学学报,2025,
                56(5):624 − 633.

                Cite this article as: GENG Sang, ZOU Xinxin, BAIMA Luobu, et al. Pharmacological mechanism of Tibetan medicine Zuotangkaca pills for
                the treatment of hypertension based on network pharmacology[J]. J China Pharm Univ, 2025, 56(5): 624 − 633.

               Pharmacological  mechanism  of  Tibetan  medicine  Zuotangkaca  pills  for  the

               treatment of hypertension based on network pharmacology
                                                                    1
                          1#
                                                     1
                                      2#
                                                                                              1,3*
                                                                              2
               GENG Sang , ZOU Xinxin , BAIMA Luobu , ZHAXI Daozhi , JI Xuejiao , DUOJIE Renqing ,
               HUANG Fengjie 2**
               1                                                        2
                Affiliated Hospital of Xizang University of Tibetan Medicine, Lhasa 850000;  State Key Laboratory of Natural Medicines, China
                                                3
               Pharmaceutical University, Nanjing 211198;  Department of Basic Studies, Xizang University of Tibetan Medicine, Lhasa 850000,
               China
               Abstract    The mechanism of Tibetan medicine Zuotangkaca pills (ZTKCW) for the treatment of hypertension
               was explored by network pharmacology and in vivo experiments. 68 active ingredients of ZTKCW and 518 drug-
               disease  targets  were  screened  by  network  pharmacology.  Eight  core  components  of  ZTKCW  (vasicolinone,
               luteolin, (–)-isocorypalmine, esculetin, liquiritigenin, etc.) and eight key targets (AKT1, TNF, IL6, and STAT3,
               etc.) were screened by network topology analysis. KEGG enrichment analysis showed that the core targets were
               mainly  enriched  in  lipids  and  atherosclerosis,  JAK/STAT,  and  inflammation-related  pathways.  An  in  vivo
               experiment was conducted using spontaneously hypertensive rats (SHR), which were gavaged with ZTKCW at
               doses of 0.41, 0.82, and 1.64 g/kg for 12 weeks, respectively. The results showed that ZTKCW at a dose of 1.64
               g/kg significantly reduced both systolic and diastolic pressure in SHR rats and decreased the phosphorylation


                                              *
                    收稿日期 2025-04-01  通信作者     Tel:13989018196 E-mail:1423106353@qq.com
                                             **
                                                Tel:13770531130 E-mail:hfj@cpu.edu.cn
                    基金项目    中央支持地方高校改革发展资金-西藏藏医药大学博士点培育项目(BSDJS-XKJS-24-02)
                    更桑和邹欣欣为共同第一作者
                    #
   87   88   89   90   91   92   93   94   95   96   97